局限性前列腺癌患者体外束放疗与体外束联合低剂量率近距离放疗推量后的患者报告结局比较
前瞻性人群为基础的比较效果分析研究纳入2011至2012年局限性前列腺癌男性,578例接受单纯体外束放疗(EBRT),109例接受EBRT联合低剂量率近距离放疗推量(EB-LDR)。多变量分析显示EB-LDR组在6、12、36个月报告更差的泌尿刺激症状功能,12个月时肠道功能更差,但36个月时肠道功能差异消失;两组性功能和激素功能无显著差异。
要点
- EB-LDR组较EBRT组在6、12、36个月报告更差的泌尿刺激症状功能。
- EB-LDR组在12个月时肠道功能更差,但36个月时未见差异。
- 两组间性功能和激素功能无显著差异。
核心结论
- 与单纯EBRT相比,EB-LDR治疗男性在1年时报告更差的肠道功能,并在3年内报告更差的泌尿刺激症状功能。
- 作者认为在考虑EB-LDR与EBRT治疗时应与患者讨论这些副作用特征。
研究设计与样本
- 前瞻性、人群为基础的比较效果分析手术与放疗研究,于2011至2012年纳入局限性前列腺癌男性。
- 578例接受EBRT,109例接受EB-LDR。
- 采用26项扩展前列腺癌指数综合测量在基线及6、12、36个月评估患者报告疾病特异性功能。
- 最小临床重要差异定义为:尿失禁6、泌尿刺激功能5、肠道功能4、性功能12、激素功能4。
- 拟合多变量线性与逻辑回归模型估计治疗对患者报告结局的影响。
主要发现
- 患者中位年龄69岁,70%为中危或高危疾病。
- EB-LDR组男性更年轻(P < .001)且接受雄激素剥夺治疗的可能性更低(P < .001)。
- 两组基线泌尿、肠道、性和激素功能相似(P > .05)。
- EB-LDR组较EBRT组报告更差的泌尿刺激症状功能:6个月调整后平均差异(AMD)-14.4(P < .001)、12个月AMD -12.9(P < .001)、36个月AMD -4.7(P = .034)。
- 12个月时EB-LDR组报告更差的肠道功能(AMD -5.8,P = .002),但36个月时未见这些差异。
关键数值与推荐
- 最小临床重要差异阈值:尿失禁6、泌尿刺激功能5、肠道功能4、性功能12、激素功能4。
- 泌尿刺激症状功能EB-LDR组较EBRT组在6个月AMD -14.4(P < .001)、12个月AMD -12.9(P < .001)、36个月AMD -4.7(P = .034)。
- 肠道功能12个月EB-LDR组较EBRT组AMD -5.8(P = .002)。
临床怎么用
- 原文结论指出,在考虑EB-LDR与EBRT治疗时应与患者讨论这些副作用特征。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To compare patient-reported disease-specific functional outcomes after external beam radiation therapy (EBRT) and EBRT combined with low-dose-rate brachytherapy prostate boost (EB-LDR) among men with localized prostate cancer. METHODS AND MATERIALS: The prospective, population-based Comparative Effectiveness Analysis of Surgery and Radiation study enrolled men with localized prostate cancer in 2011 to 2012. The 26-item Expanded Prostate Cancer Index Composite measured patient-reported disease-specific function at baseline and at 6, 12, and 36 months. Higher domain scores indicate better function. Minimal clinically important difference was defined as 6 for urinary incontinence, 5 for urinary irritative function, 4 for bowel function, 12 for sexual function, and 4 for hormonal function. Multivariable linear and logistic regression models were fit to estimate the effect of treatment on patient-reported outcomes. RESULTS: Five-hundred seventy-eight men received EBRT and 109 received EB-LDR. Median patient age was 69 years, and 70% had intermediate- or high-risk disease. Men in the EB-LDR group were younger (P < .001) and less likely to receive androgen deprivation therapy (P < .001). Baseline urinary, bowel, sexual, and hormonal function was similar between treatment groups (P > .05). On multivariable analyses, men receiving EB-LDR reported worse urinary irritative function at 6 months (adjusted mean difference [AMD] -14.4, P < .001), 12 months (AMD -12.9, P < .001), and 36 months (AMD -4.7, P = .034) than men receiving EBRT. At 12 months, men receiving EB-LDR reported worse bowel function (AMD -5.8, P = .002), but these differences were not seen at 36 months. There were no significant differences in sexual or hormone function between treatment groups. CONCLUSIONS: Men treated with EB-LDR report worse bowel function at 1 year and worse urinary irritative function through 3 years compared with men treated with EBRT alone. These side effect profiles should be discussed with patients when considering EB-LDR versus EBRT treatment.
引用
- Lee DJ, Barocas DA, Zhao Z, et al. Comparison of Patient-reported Outcomes After External Beam Radiation Therapy and Combined External Beam With Low-dose-rate Brachytherapy Boost in Men With Localized Prostate Cancer. Int J Radiat Oncol Biol Phys. 2018. PMID: 30102188. doi:10.1016/j.ijrobp.2018.05.043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。